Ki
Kiadis (Sanofi)
Amsterdam NLFounded 200580 employees
Private CapbiotechAcquiredHematology
Platform: K-NK002 NK
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Capiderotide | KIA-8268 | Phase 1/2 | 1 | APOC3 | SchizophreniaPancreatic Ca | ||
| KIA-7239 | KIA-7239 | Phase 2/3 | 2 | TYK2 | T2DDLBCL | ||
| KIA-7048 | KIA-7048 | Phase 3 | 3 | SHP2 | UCADHD | ||
| KIA-5275 | KIA-5275 | Phase 2/3 | 2 | BCMA | Schizophrenia |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (9)